**Editor**

Josef S Smolen

**Associate Editors**

Francis Berenbaum  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes  
Thomas Pap  
David Pisetky  
Désirée van der Heijde  
Kazuhiko Yamamoto

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 3655 5889  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)

**Disclaimer:** The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

**Copyright:** © 2020 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

*ARD* is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases* (ISSN No: 0003-4967) is distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431. POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o WVN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

**Editorial**

- 1 Greetings from the editor 2020  
*J S Smoleni,*

**Recommendations**

- 3 EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies  
*M Ramos-Casals, P Brito-Zerón, S Bombardieri, H Bootsma, S De Vita, T Dörner, B A Fisher, J-E Gottenberg, G Hernandez-Molina, A Kocher, B Kostov, A A Kruize, T Mandl, W-F Ng, S Retamozo, R Seror, Y Shoenfeld, A Sisó-Almirall, A G Tzioufas, C Vitali, S Bowman, X Mariette, On behalf of the EULAR-Sjögren Syndrome Task Force Group*

- 19 2018 Update of the EULAR recommendations for the management of large vessel vasculitis  
*B Hellmich, A Agueda, S Monti, F Buttgerit, H de Boysson, E Brouwer, R Cassie, M C Cid, B Dasgupta, C Dejaco, G Hatemi, N Hollinger, A Mahr, S P Mollan, C Mukhtyar, C Ponte, C Salvarani, R Sivakumar, X Tian, G Tomasson, C Turesson, W Schmidt, P M Villiger, R Watts, C Young, R A Luqmani*

- 31 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout  
*P Richette, M Doherty, E Pascual, V Barskova, F Becce, J Castaneda, M Coyfish, S Guillo, T Jansen, H Janssens, F Lioté, C D Mallen, G Nuki, F Perez-Ruiz, J Pimentao, L Punzi, A Pywell, A K So, A-K Tausche, T Uhlig, J Zavada, W Zhang, F Tubach, T Bardin*

- 39 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases  
*V Furer, C Rondaan, M W Heijstek, N Agmon-Levin, S van Assen, M Bijl, F C Breedveld, R D'Amelio, M Dougados, M C Kapetanovic, J M van Laar, A de Thurah, R BM Landewé, A Molto, U Müller-Ladner, K Schreiber, L Smolar, J Walker, K Warnatz, N M Wulffraat, O Elkayam*

- 53 2019 EULAR recommendations for the generic core competences of health professionals in rheumatology  
*L Edelaar, E Nikiphorou, G E Fragoulis, A Iagnocco, C Haines, M Bakkers, L Barbosa, N Cikes, M Ndosi, J Prindahl, Y Prior, P Pehelnikova, V Ritschl, V S Schäfer, H Smucrova, I Storrønning, M Testa, D Wiek, T P M Vliet Vlieland*

- 61 2018 update of the EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis  
*B Bech, J Prindahl, A van Tubergen, M Voshaar, H A Zangi, L Barbosa, C Boström, B Boteva, F Carubbi, F Fayet, R J O Ferreira, K Hoepfer, A Kocher, M L Kukkurainen, V Lion, P Minnock, A Moretti, M Ndosi, M Pavic Nikolic, M Schirmer, H Smucrova, J de la Torre-Aboki, J Waite-Jones, Y van Eijk-Hustings*

- 69 EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases  
*L Gossec, J Kedra, H Servy, A Pandit, S Stones, F Berenbaum, A Finckh, X Baraliakos, T A Stamm, D Gomez-Cabrero, C Pristipino, R Choquet, G R Burmester, T R D J Radstake*

**Criteria**

- 77 The 2019 American College of Rheumatology/ European League Against Rheumatism classification criteria for IgG4-related disease  
*Z S Wallace, R P Naden, S Chari, H K Choi, E Della-Torre, J-F Dicaire, P A Hart, D Inoue, M Kawano, A Khosroshahi, M Lanzillotta, K Okazaki, C A Perugino, A Sharma, T Saeki, N Schleinitz, N Takahashi, H Umehara, Y Zen, J H Stone, Members of the ACR/EULAR IgG4-RD Classification Criteria Working Group*

**Viewpoint**

- 88 Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019  
*K L Winthrop, M E Weinblatt, J Bathon, G R Burmester, P J Mease, L Crofford, V Bykerk, M Dougados, J T Rosenbaum, X Mariette, J Sieper, F Melchers, B N Cronstein, F C Breedveld, J Kalden, J S Smolen, D Furst*

MORE CONTENTS ►



EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

C O P E

Member since 2008

J.M00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics


<http://publicationethics.org/>



When you have finished with this please recycle it


## Rheumatoid arthritis

- 94** Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial  
 *Y Tanaka, K Oba, T Koike, N Miyasaka, T Mimori, T Takeuchi, S Hirata, E Tanaka, H Yasuoka, Y Kaneko, K Murakami, T Koga, K Nakano, K Amano, K Ushio, T Atsumi, M Inoo, K Hatta, S Mizuki, S Nagaoka, S Tsunoda, H Dobashi, N Horie, N Sato*


- 103** Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population  
 *T Kishikawa, Y Maeda, T Nii, D Motooka, Y Matsumoto, M Matsushita, H Matsuoka, M Yoshimura, S Kawada, S Teshigawara, E Oguro, Y Okita, K Kawamoto, S Higa, T Hirano, M Narazaki, A Ogata, Y Sasaki, S Nakamura, H Inohara, A Kumanogoh, K Takeda, Y Okada*

- 112** FGFR3 deficiency enhances CXCL12-dependent chemotaxis of macrophages via upregulating CXCR7 and aggravates joint destruction in mice  
*L Kuang, J Wu, N Su, H Qi, H Chen, S Zhou, Y Xiong, X Du, Q Tan, J Yang, M Jin, F Luo, J Ouyang, B Zhang, Z Wang, W Jiang, L Chen, S Chen, Z Wang, P Liu, L Yin, F Guo, C Deng, D Chen, C Liu, Y Xie, Z Ni, L Chen*


## Psoriatic arthritis

- 123** A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial  
 *P J Mease, J S Smolen, F Behrens, P Nash, S Liu Leage, L Li, H Tahir, M Gooderham, E Krishnan, H Liu-Seifert, P Emery, S G Pillai, P S Helliwell, The SPIRIT H2H study group*


## Spondyloarthritis

- 132** Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in ankylosing spondylitis patients, as well as the effects of TNFi therapy upon microbiome composition  
 *J Yin, P R Sternes, M Wang, J Song, M Morrison, T Li, L Zhou, X Wu, F He, J Zhu, M A Brown, H Xu*


## Systemic lupus erythematosus

- 141** Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial  
 *J He, R Zhang, M Shao, X Zhao, M Miao, J Chen, J Liu, X Zhang, X Zhang, Y Jin, Y Wang, S Zhang, L Zhu, A Jacob, R Jia, X You, X Li, C Li, Y Zhou, Y Yang, H Ye, Y Liu, Y Su, N Shen, J Alexander, J Guo, J Ambrus, X Lin, D Yu, X Sun, Z Li*

## Sjögren's syndrome

- 150** Antigen-driven selection of antibodies against SSA, SSB and the centromere 'complex', including a novel antigen, MIS12 complex, in human salivary glands  
 *M Takeshita, K Suzuki, Y Kaneda, H Yamane, K Ikeura, H Sato, S Kato, K Tsunoda, H Arase, T Takeuchi*

## Letters

- 159** Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?  
*J K Wallman, E Mogard, J Marsal, K Andréasson, A Jöud, M Geijer, L E Kristensen, E Lindqvist, T Olofsson*
- 161** Both HLA class I and II regions identified as genome-wide significant susceptibility loci for adult-onset Still's disease in Chinese individuals  
 *Z Li, H-L Liu, J Chen, T Zeng, L He, M Li, C Luo, S Liu, T-T Ding, K Yimaiti, J Teng, X Li, Y Ding, X Cheng, J Zhou, J Ye, J Ji, Y-T Su, H Shi, Y Sun, C Gao, Q Hu, H Chi, X Yuan, Z Zhou, D Wang, K Wang, C-G Li, Y Sun, Y Niu, L-J Chen, J Xu, L Wu, Z Zhou, D Pan, H Niu, Y Shi, C Yang*

- 163** Molecular typing of cryoglobulins by mass spectrometry  
*A YS Lee, T Chataway, T P Gordon, J J Wang*

- 164** Dysfunctional missense variant of *OAT10/SLC22A13* decreases gout risk and serum uric acid levels  
 *T Higashino, K Morimoto, H Nakaoka, Y Toyoda, Y Kawamura, S Shimizu, T Nakamura, K Hosomichi, A Nakayama, K Ooyama, H Ooyama, T Shimizu, M Ueno, T Ito, T Tamura, M Naïto, H Nakashima, M Kawaguchi, M Takao, Y Kawai, N Osada, K Ichida, K Yamamoto, H Suzuki, N Shinomiya, I Inoue, T Takada, H Matsuo*

**Electronic pages**

- e1** Imputation-based analysis of MICA alleles in the susceptibility to ankylosing spondylitis  
*X Zhou, J D Reveille*
- e2** Response to: Imputation-based analysis of MICA alleles in the susceptibility to ankylosing spondylitis by Zhou *et al*  
*A Cortes, M A Brown*
- e3** ANA testing in 'real life'  
*M Infantino, M Manfredi, P Soda, M Merone, A Afeltra, A Rigon*
- e4** Response to: 'ANA testing in "real life"' by Infantino *et al*  
*D S Pisetsky, D M Spencer, P E Lipsky, B H Rovin*
- e5** Harmonisation of laboratory tests for rheumatic diseases: still a long way to go  
*L Van Hoovels, X Bossuyt*
- e6** Antinuclear autoantibodies: discordance among four different assays  
*Y Pacheco, D M Monsalve, Y Acosta-Ampudia, C Rojas, J-M Anaya, C Ramirez-Santana*
- e7** Response to: "Antinuclear autoantibodies: discordance among four different assays" by Pacheco *et al*  
*D S Pisetsky, D M Spencer, P E Lipsky, B Rovin*
- e8** Biomarkers: to be or not to be  
*S Yavuz, L Rönnblom*
- e9** Galectin-9 reflects the interferon signature and correlates with disease activity in systemic autoimmune diseases. Response to: 'Biomarkers: to be or not to be' by Yavuz and Rönnblom  
*L L van den Hoogen, E H M van der Heijden, M R Hillen, J S Mertens, R D E Fritsch-Stork, T R D J Radstake, J A G van Roon*
- e10** Prolonged treatment with Tadekinig alfa in adult-onset Still's disease  
*U Kiltz, D Kiefer, J Braun, E J Schiffrin, C Girard-Guyonvarc'h, C Gabay*
- e11** Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect  
*V Germain, M Scherlinger, T Barnette, T Schaevebeke, On behalf of the Fédération Hospitalo-universitaire ACRONIM*
- e12** Correction: *The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. A meta-analysis and functional study*